A study of dapagliflozin in Chinese adult patients with chronic kidney disease

Study identifier:D169AC00008

ClinicalTrials.gov identifier:NCT06610526

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients with Chronic Kidney Disease

Medical condition

Chronic Kidney Disease

Phase

Phase 4

Healthy volunteers

No

Study drug

Dapagliflozin

Sex

All

Estimated Enrollment

700

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 10 Sept 2024
Estimated Primary Completion Date: 21 Jun 2027
Estimated Study Completion Date: 21 Jun 2027

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria